Skip to main content

O'Neill Vincent's Form 4/A amendment

Amended

BioXcel Therapeutics, Inc. (BTAIQ) · filed Jun 18, 2024

Accession no.
0001104659-24-072998
Filed
Jun 18, 2024
Trade date
Mar 14-15, 2023
Filing delay
462 days
Rule 10b5-1 plan
Not checked
Original filed
Mar 16, 2023

This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $16.6K. It was filed 462 days after the trade.

This amendment replaces 0001104659-23-033402 (filed Mar 16, 2023).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
O'Neill VincentCIK 0001672718Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 14, 2023Common StockMOption exerciseAcquired+2,084––2,084Direct
Mar 15, 2023Common StockSSaleDisposed−845$19.70−$16,646.51,239Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 14, 2023Common StockMOption exerciseDisposed−2,084$0.00$06,253Direct
Mar 15, 2023Common StockAGrant or awardAcquired+9,000$0.00$09,000Direct
Mar 15, 2023Common StockAGrant or awardAcquired+32,000$0.00$032,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)